Athira Pharma, Inc. — Director's Dealing 2023

Jun 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2023-06-02

Reporting Person: MOEBIUS HANS (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-18	Common Stock	A	7764	$2.41	Acquired	73600	Direct
2023-06-02	Common Stock	M	7882	$1.35	Acquired	81482	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-02	Stock Option (Right to Buy)	$1.35	M	7882	Disposed	2029-08-14	Common Stock (7882)	Direct

Footnotes

F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2022 through May 18, 2023. This transaction is also exempt under Rule 16b-3(c).

F2: The Purchase Period ended May 18, 2023 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2022.

F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2023.

F4: One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.